Competitor Analysis: Interleukin-6 (IL-6) Inhibitors and IL-6 Receptor (IL-6R) Antagonists

Publisher: La Merie Publishing
Pages: 23
Format: PDF
Product Line:
Competitor Analysis
Product Line:
Target Pipeline
Product Code: LMCA0049
Release Date: October of 2012

150.00 €
Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
License:
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Competitor Analysis: Interleukin-6 (IL-6) Inhibitors and IL-6 Receptor (IL-6R) Antagonists

Product description

The present Competitive Intelligence Report about Interleukin-6 (IL-6) Inhibitors and IL-6 Receptor (IL-6R) Antagonists for treatment of rheumatoid arthritis and multiple myeloma provides a competitor evaluation in the field of R&D projects with Interleukin-6 (IL-6) Inhibitors and IL-6 Receptor (IL-6R) Antagonists as of October 2012. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Although the causes of rheumatoid arthritis are not fully understood, constitutive overproduction of interleukin-6 (IL-6), a multifunctional cytokine that regulates immune response, inflammatory reaction and bone metabolism, is thought to play a major pathological role in RA. With the recent approval of tocilizumab, a humanized anti-IL-6 receptor antibody originating from Chugai and under development at Roche in Western countries, this target has become clinically validated and now can show its commercial potential in competition with TNF blockers.

The report includes a compilation of currently active projects in research and development of interleukin-6 (IL-6) and IL-6 receptor (IL-6R) antagonists. In addition, the report lists company-specific R&D pipelines of IL-6/R antagonists. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category/Therapeutic Area,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Competitor Analysis: Interleukin-6 (IL-6) Inhibitors and IL-6 Receptor (IL-6R) Antagonists

Index

  • IL-6 Inhibitors
  • IL-6R Antagonists
  • About La Merie



The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top